Transcode Therapeutics Inc
RNAZ
NASDAQ
Biotechnology
$3.28
USD
-0.20 (-5.75%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.68M
Volume 40.5K
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
CEO
Dr. Philippe Calais
HQ
Boston, MASSACHUSETTS, US
Founded
2021
Employees
7
Key Metrics
2 metrics our research team weighs before forming a view on RNAZ.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
ROE (TTM)
-3225.2%
-2977.3 pp
Free Cash Flow (TTM)
$-21.40M
—
Financial Snapshot
Revenue
$0
— YoY
Gross Margin
—
— YoY
Net Income
$-40.36M
-58.2%
YoY
Operating Cash Flow
$-21.40M
-71.2%
YoY
Key Statistics
Open
$3.50
Previous Close
$3.48
Day Range
$3.21 - $3.70
52 Week Range
$3.21 - $20.99
Volume
40.5K
Average Volume (10 Days)
20.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$3.68M
P/E Ratio (TTM)
—
Price / Book
2.94
Financial Highlights
Return on Assets
-25.7%
Return on Equity
-3225.2%
Revenue (TTM)
$0
Net Income (TTM)
$-40.36M
Diluted EPS (TTM)
-$48.61
Total Cash (MRQ)
$12.84M
Levered FCF (TTM)
$-21.40M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
